-+ 0.00%
-+ 0.00%
-+ 0.00%

Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR

PUBT·04/22/2026 12:03:58
Listen to the news
Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR
  • Vyome presented full Phase 2 investigator-initiated study results for VT-1953 at AACR 2026 on April 21, 2026.
  • VT-1953 showed clinically meaningful improvement in malignant fungating wound malodor versus vehicle control.
  • Patient-reported quality of life improved on malodor impact measures, with pain also easing; exudate levels did not change.
  • No treatment-associated adverse effects were reported in study.
  • Vyome plans to advance VT-1953 into registrational studies, citing third-party estimates of USD 2.2 billion total addressable U.S. market for malignant fungating wound symptom treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260422702864) on April 22, 2026, and is solely responsible for the information contained therein.